CENSORSHIP HAS ARRIVED

But not for me

The federal government has now ordered investigators at the National Cancer Institute to submit their reasearch for review and approval to a “clearance team” under the control of RFK, before publication for certain “controversial, high profile or sensitive topics”. Among these topics are COVID, autism and many more. In essense, Trump and RFK have now muzzled what research scientists may publish.

https://www.propublica.org/article/national-cancer-institute-flagged-topics-vaccines-autism-rfk-jr

Fortunately for me, I am not a federal employee and don’t have to submit what I write to RFK’s “clearance team”. At least not yet. So, I am going to do updates on the latest research on these banned topics. RFK can block HHS employees but he can’t block me.

Here is the latest from UPTODATE on the epidemiology, virology and prevention of COVID -19.

SUMMARY AND RECOMMENDATIONS

●Burden of disease – Since the first reports of coronavirus disease 2019 (COVID-19) and identification of the novel coronavirus that causes it, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection has spread to every corner of the globe, causing disease year-round. Reinfections are increasingly common.

●Variants of concern – Several variants of SARS-CoV-2 have emerged that are notable because of the potential for increased transmissibility. Omicron variant sublineages are associated with a higher risk of reinfection in individuals previously infected with other variants and breakthrough infection in vaccinated individuals, but they are also associated with less severe disease.

●Modes of transmission – Short-range aerosol person-to-person transmission is the primary means of SARS-CoV-2 transmission. When a person with infection coughs, sneezes, or talks, virus suspended on tiny particles can infect a susceptible contact if it is inhaled or makes direct contact with the mucous membranes. The highest risk for infection is with close-range contact; SARS-CoV-2 can also be transmitted over longer distances, particularly in enclosed, poorly ventilated spaces.

●Period of infectiousness – Individuals with SARS-CoV-2 infection are most infectious in the earlier stages of infection (starting prior to the development of symptoms). Transmission after 7 to 10 days of illness is unlikely, particularly for otherwise immunocompetent patients with nonsevere infection. Prolonged viral RNA shedding after symptom resolution is not clearly associated with prolonged infectiousness.

●Personal preventive measures – In settings where there is community transmission of SARS-CoV-2, personal measures to reduce the risk of transmission include vaccination, hand and respiratory hygiene, masking, improving indoor ventilation and avoiding poorly ventilated crowded areas, being vigilant for signs and symptoms of COVID-19, and avoiding close contact with ill individuals.

●Pre-exposure prophylaxis – COVID-19 vaccination is the optimal method of pre-exposure prophylaxis. For selected immunocompromised patients expected to have suboptimal immune response to vaccination (eg, those with active hematologic malignancy, recent stem cell transplantation, or history of solid organ transplantation), we also suggest pre-exposure prophylaxis with the monoclonal antibody pemivibart to reduce the risk of severe COVID-19 (Grade 2C). Supportive data are limited to immunogenicity studies and indirect observational data with other monoclonal antibodies. Pemivibart should only be used if it remains active against the dominant circulating variants.

This information is current as of February 2025

Please feel free to share this “controversial, high profile and sensitive” information.